Did Rocket Lab's profitability actually improve in Q3 2025?

Partially. Gross profit more than doubled to $57.3M and adjusted EBITDA loss narrowed to $26.3M from $30.9M. However, the GAAP operating loss widened to $59.0M from $51.9M as operating expenses rose sharply. The reported net loss improvement to $18.3M relied heavily on a $41.1M tax benefit, so it should not be read as operating improvement.

How much cash does Rocket Lab have, and how long can it fund operations?

Cash and cash equivalents were $807.9M at September 30, 2025, plus $215.1M in marketable securities (current and non-current), and management cites over $1B in total liquidity. Operating cash burn was $101.0M and capex was $106.6M over nine months, so the company is funding a heavy investment cycle, largely through equity raises. Investors should watch continued dilution, since the share count rose from about 504M to 496M outstanding (plus 46M Series A preferred) and weighted shares increased year over year.

What is driving the revenue growth and margin expansion?

Service revenue rose to $51.0M from $25.4M, roughly doubling, and product revenue grew to $104.0M from $79.4M. Management cites record launch contract wins (17 Electron dedicated launch contracts in Q3) and a record backlog. Gross margin expansion came from higher revenue against a cost base that grew more slowly, though non-GAAP gross margin of 41.9% was partly supported by excluding amortization and stock-based compensation.

What are the key near-term catalysts and risks?

Near-term catalysts include the Q4 2025 targeted record launch count (20+ launches), continued HASTE hypersonic missions, and Neutron's arrival at Launch Complex 3 in Q1 2026, with first launch to follow after qualification testing. Key risks include Neutron schedule slippage (the schedule has already been updated), the integration of recent acquisitions such as Geost and Mynaric, continued operating losses, and the pace of further equity issuance to fund M&A and capex. Note that Q4 guidance implies only a modest EBITDA loss improvement, and the 8-K discloses no reason for the Ocko board resignation beyond the absence of any disagreement.

RKLB 8-K: Earnings & Results & Leadership Changes

01—Abstract

Summary

Summary of the 8-K filed November 10, 2025. Cited figures are marked; the original filing is the authoritative source.

Rocket Lab (RKLB) reported record third-quarter 2025 revenue of $155.1 million^a, up 48% year-over-year from $104.8 million, with GAAP gross margin of 37% (GAAP gross profit of $57.3 million versus $28.0 million a year earlier).

Operating loss widened to $59.0 million^b from $51.9 million as operating expenses grew 46% to $116.3 million, driven by higher R&D (up to $70.7 million) and SG&A (up to $45.6 million), including $5.1 million of transaction costs tied to acquisitions. Net loss narrowed sharply to $18.3 million, or $0.03 per share, from $51.9 million, primarily because of a $41.1 million income tax benefit. Adjusted EBITDA was a loss of $26.3 million, compared with a loss of $30.9 million in the prior-year quarter.

Balance sheet strength improved materially. Cash and cash equivalents rose to $807.9 million^c from $271.0 million at year-end 2024, and management states total liquidity exceeds $1 billion after the at-the-market equity program, which raised $865.5 million gross during the first nine months. Total assets grew to $2.22 billion, with goodwill and intangibles rising substantially after the Geost acquisition (up to $325 million, cash plus equity) and the Mynaric restructuring.

Cash burn remains significant: net cash used in operating activities was $101.0 million^d for the nine months, and capital expenditures were $106.6 million, largely related to Neutron and Launch Complex 3 buildout. For Q4 2025, management guided to revenue of $170 million to $180 million, GAAP gross margin of 37% to 39%, and adjusted EBITDA loss of $23 million to $29 million, and expects to surpass its prior annual launch record and reach 20+ launches for the year.

Neutron is now expected to arrive at Launch Complex 3 in Q1 2026, with first launch thereafter pending qualification testing. The 8-K also discloses that director Matt Ocko resigned from the board effective November 30, 2025, with no disagreement with the company cited.

02—Key points

Key Highlights

Record Q3 2025 revenue of $155.1M, up 48% YoY, with GAAP gross margin of 37% versus roughly 27% a year earlier
Net loss narrowed to $18.3M ($0.03 per share) from $51.9M, but this was mainly aided by a $41.1M income tax benefit; operating loss widened to $59.0M
Adjusted EBITDA loss of $26.3M, improved from a $30.9M loss in Q3 2024
Cash and equivalents rose to $807.9M; management cites over $1B in liquidity after $865.5M of ATM equity proceeds year-to-date
Acquisitions expanded the balance sheet: goodwill rose to $217.7M and intangibles to $232.0M, following the Geost acquisition (up to $325M) and Mynaric restructuring
Q4 2025 guidance: revenue of $170M to $180M, GAAP gross margin of 37% to 39%, and adjusted EBITDA loss of $23M to $29M
Neutron arrival at Launch Complex 3 pushed to Q1 2026, and director Matt Ocko resigned effective November 30, 2025

03—Questions

Frequently Asked Questions

Did Rocket Lab's profitability actually improve in Q3 2025?
Partially. Gross profit more than doubled to $57.3M and adjusted EBITDA loss narrowed to $26.3M from $30.9M. However, the GAAP operating loss widened to $59.0M from $51.9M as operating expenses rose sharply. The reported net loss improvement to $18.3M relied heavily on a $41.1M tax benefit, so it should not be read as operating improvement.
How much cash does Rocket Lab have, and how long can it fund operations?
Cash and cash equivalents were $807.9M at September 30, 2025, plus $215.1M in marketable securities (current and non-current), and management cites over $1B in total liquidity. Operating cash burn was $101.0M and capex was $106.6M over nine months, so the company is funding a heavy investment cycle, largely through equity raises. Investors should watch continued dilution, since the share count rose from about 504M to 496M outstanding (plus 46M Series A preferred) and weighted shares increased year over year.
What is driving the revenue growth and margin expansion?
Service revenue rose to $51.0M from $25.4M, roughly doubling, and product revenue grew to $104.0M from $79.4M. Management cites record launch contract wins (17 Electron dedicated launch contracts in Q3) and a record backlog. Gross margin expansion came from higher revenue against a cost base that grew more slowly, though non-GAAP gross margin of 41.9% was partly supported by excluding amortization and stock-based compensation.
What are the key near-term catalysts and risks?
Near-term catalysts include the Q4 2025 targeted record launch count (20+ launches), continued HASTE hypersonic missions, and Neutron's arrival at Launch Complex 3 in Q1 2026, with first launch to follow after qualification testing. Key risks include Neutron schedule slippage (the schedule has already been updated), the integration of recent acquisitions such as Geost and Mynaric, continued operating losses, and the pace of further equity issuance to fund M&A and capex. Note that Q4 guidance implies only a modest EBITDA loss improvement, and the 8-K discloses no reason for the Ocko board resignation beyond the absence of any disagreement.

04—Continue

← View all 8-K filings